Compare Ascendis Pharma A/S (ASND) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Wheaton Precious Metals Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Wheaton Precious Metals Corp trades at $108.75 (market cap $49.85B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.8× Ascendis Pharma A/S's market cap, and Wheaton Precious Metals Corp pays a 0.71% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WPM | |
|---|---|---|
Market Cap | $17.74B | $49.85B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $165.72 |
52-Week Low | $163.32 | $88.32 |
Enterprise Value | $18.11B | $47.69B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Wheaton Precious Metals (WPM) trades at $110.05, down 0.54% on the day, amid a bearish technical signal. The company exhibits strong fundamentals with 2025 revenue of $2.31B, net income of $1.47B, and consistent earnings beats. Analyst consensus is strongly bullish with a $163 price target, though recent news highlights sensitivity to precious metal price volatility.
WPM offers a compelling growth story with robust profitability and positive cash flow, but faces risks from commodity price swings and acquisition integration. The stock's current discount to analyst targets presents a potential opportunity for long-term investors, contingent on stable metal prices and execution of production outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
